Pharmaceutical

BGB-30813 by BeiGene for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

BGB-30813 is under clinical development by BeiGene and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).

Dec 26, 2023 - 18:00
BGB-30813 is under clinical development by BeiGene and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).
Read the original article

Tags:

Previous Article

ORB-011 by Orionis Biosciences for Head And Neck Squamous Cell Carcinoma (HNSC):...

Next Article

NT-175 by Neogene Therapeutics for Head And Neck Squamous Cell Carcinoma (HNSC):...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Bavarian Nordic gains US contract for additional mpox vaccine

Bavarian Nordic gains US contract for additional mpox v...

Sep 26, 2024

Kid EDV by ImmunityBio for Pediatric Diffuse Intrinsic ...

Jun 5, 2023

Novartis eyes $2.9bn MorphoSys buyout to expand oncology pipeline

Novartis eyes $2.9bn MorphoSys buyout to expand oncolog...

Feb 6, 2024